Drugs / CBLB612
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02778763 | Dec 2015 → Jul 2016 | breast cancer | BioLab 612 LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBLB612 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02778763 ↗ |
| Route | Subcutaneous | “4 μg CBLB612 SQ” NCT02778763 ↗ |